Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Stomach Neoplasms 128Esophageal Neoplasms 127Esophageal Squamous Cell Carcinoma 77Adenocarcinoma Of Esophagus 36Pancreatic Neoplasms 30Colorectal Neoplasms 25Carcinoma, Non-Small-Cell Lung 23Breast Neoplasms 22Neoplasms 21Neoplasm Metastasis 19Ovarian Neoplasms 16Melanoma 12Lung Neoplasms 11Carcinoma, Squamous Cell 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Adenocarcinoma 10Endometrial Neoplasms 9Carcinoma, Renal Cell 9Advanced Gastric Cancer 9Squamous Cell Carcinoma of Head and Neck 8Peritoneal Neoplasms 8Colonic Neoplasms 8Carcinoma, Ovarian Epithelial 8Anus Neoplasms 8Digestive System Neoplasms 7Prostatic Neoplasms 6Cholangiocarcinoma 6Biliary Tract Neoplasms 6Uterine Cervical Neoplasms 5Sarcoma 5

Interventions

Gemcitabine 4pembrolizumab 3napabucasin 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3lenvatinib 2entinostat 2Taxes 2Sunitinib 2Sorafenib 2Paclitaxel 2Leucovorin 2Fluorouracil 2Cisplatin 2Bevacizumab 2pralsetinib 1linifanib 1durvalumab 1Radiofrequency Ablation 1Pemetrexed 1Nivolumab 1Immunotherapy 1Endoscopic Mucosal Resection 1Cobicistat 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × Paclitaxel × Gastrointestinal × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡